---
title: "Truking (300358): Won the bid for the procurement project of the Biotechnology Technology Transfer and Transformation Center (Guangzhou) Co., Ltd., with a bid amount of 9.78 million yuan"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/289169479.md"
description: "Truking (300358) announced that it won the bid for the procurement project of the Biomedical Technology Transfer and Transformation Center (Guangzhou) Co., Ltd., with a bid amount of 9.78 million yuan. The project involves the procurement of equipment for the preparation of immune cells and the hive culture system"
datetime: "2026-06-09T10:00:51.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/289169479.md)
  - [en](https://longbridge.com/en/news/289169479.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/289169479.md)
generator: "portal-rs"
---

# Truking (300358): Won the bid for the procurement project of the Biotechnology Technology Transfer and Transformation Center (Guangzhou) Co., Ltd., with a bid amount of 9.78 million yuan

According to Tongbi Finance, data from Qichacha shows that based on the "Announcement of the Bidding Results for the Construction of the Public Transformation Platform for the Regional Technology Transfer and Transformation Center of National Universities (Biomedicine Sub-center in the Guangdong-Hong Kong-Macao Greater Bay Area) (Phase I) Equipment Procurement (Immunocell Preparation Full Station and Hive Culture System)," Truking Technology Co., Ltd. announced on June 9, 2026, that it won the bid for the procurement project of the Biomedicine Technology Transfer and Transformation Center (Guangzhou) Co., Ltd., with a bid amount of 9.78 million yuan.

Related listed company: Truking Technology (300358.SZ)

*Tongbi Finance Tip:*

*Truking Technology (300358.SZ) reported an operating income of 5.763 billion yuan in 2025, with an operating income growth rate of -1.14%. The net profit attributable to the parent company was 255 million yuan, with a net profit growth rate of 156.26%, and a return on net assets of 5.89%.*

*In the first quarter of 2026, the company's operating income was 1.109 billion yuan, with an operating income growth rate of 2.40%. The net profit attributable to the parent company was 68 million yuan, with a net profit growth rate of 892.43%.*

*Currently, the company belongs to the industrial sector, with the main product type being pharmaceutical machinery. The 2025 report indicates that the main composition of its business includes detection and packaging solutions and single machines: 23.85%; sterile preparation solutions and single machines: 19.74%; accessories: 16.6%; pharmaceutical water equipment and engineering system integration: 14.85%; bioengineering single machines and systems: 11.2%; solid preparation equipment: 9.5%; engineering design services: 3.55%; other products: 0.45%; other businesses: 0.26%.*

### Related Stocks

- [300358.CN](https://longbridge.com/en/quote/300358.CN.md)

## Related News & Research

- [Leave a Nest Capital president makes first appearance at TECH GARAGE Seminar in Malaysia](https://longbridge.com/en/news/297597370.md)
- [Theorem Launches Exchange Infrastructure Built for the Next Phase of Tokenized Asset Markets](https://longbridge.com/en/news/297658497.md)
- [CSPC’s SYS6010 Wins Third Breakthrough Therapy Tag in High-Need Cancer Indications](https://longbridge.com/en/news/297638498.md)
- [Embodied-AI startup PsiBot raises over $100 million with industrial investors joining](https://longbridge.com/en/news/297272077.md)
- [Kitron plans new 8,850-sq-meter factory in Denmark’s Horsens amid growth push](https://longbridge.com/en/news/297664487.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**